Anti-TNFs in axial spondyloarthritis
Kocijan R, Muschitz C, Rech J (2015)
Publication Type: Journal article
Publication year: 2015
Journal
Book Volume: 165
Pages Range: 10-3
Journal Issue: 1-2
DOI: 10.1007/s10354-014-0338-1
Abstract
Since there is no evidence regarding the efficacy of conventional synthetic disease modifying anti-rheumatic drugs in the improvement of axial spondyloarthritis (SpA), anti-tumor necrosis factors (anti-TNFs) are recommended if nonsteroidal anti-inflammatory drugs fail, or in case of high disease activity. Anti-TNFs show encouraging data regarding pain reduction, improved mobility and quality of life in both ankylosing spondylitis and non-radiographic axial spondyloarthritis. However, withdrawal of anti-TNF therapy leads to relapse of disease activity in SpA. Moreover, osteoproliferation does not seem to be influenced by anti-TNFs.
Involved external institutions
Austria (AT)How to cite
APA:
Kocijan, R., Muschitz, C., & Rech, J. (2015). Anti-TNFs in axial spondyloarthritis. Wiener Medizinische Wochenschrift, 165(1-2), 10-3. https://dx.doi.org/10.1007/s10354-014-0338-1
MLA:
Kocijan, Roland, Christian Muschitz, and Juergen Rech. "Anti-TNFs in axial spondyloarthritis." Wiener Medizinische Wochenschrift 165.1-2 (2015): 10-3.
BibTeX: Download